Bay­er ex­its Eu­rope pact with Moberg for nail fun­gus drug af­ter Phase 3 fail

Moberg Phar­ma’s Terclara has flunked a late-stage test eval­u­at­ing less fre­quent main­te­nance dos­ing for fun­gal nail in­fec­tion, prompt­ing Bay­er to pull out of planned launch …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER